Akeso's Lung Cancer Drug Shows Improved Survival in Phase 3 Trial
Akeso (AKESF) reported that its experimental lung cancer drug ivonescimab improved overall survival compared to a standard immunotherapy regimen for advanced squamous non-small cell lung cancer. The results from the Phase 3 trial could position Akeso's treatment as an alternative in this competitive market segment.
Topics: cancer treatment immunotherapy lung cancer